Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Eton Pharmaceuticals, Inc./ 8-K

Current Report · Items 8.01, 9.01 · 8-K

Eton Pharmaceuticals, Inc.

ETONNASDAQEQUITYCurrent

Other Events

Item 8.01: Other Events On September 28, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules. The Company has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.…

Filed Sep 28, 2026Accepted Sep 28, 2026, 7:15 AM EDTCIK 1710340Accession 0001437749-26-031281
View company →Permanent SEC source ↗
Share

Press release in this filing

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules →

Company context

Current securities

ETONNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of AssetsOct 14, 2026
  2. 4/A filingAug 31, 2026
  3. 4 filingAug 28, 2026
  4. 144 filingAug 28, 2026
  5. 4 filingAug 24, 2026

Registered securities in this filing

ETON PHARMACEUTICALS, INC. · 8-K · Filed 2026-09-28

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
ETON
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: d20268K

Dimensions: Not supplied

Accession 000143774926031281 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01: Other Events On September 28, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules. The Company has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.